Post-earnings recap
Reported
Thu, Nov 6, 2025
EPS actual
$-0.74
EPS est.
$-0.76
EPS surprise
+3.01%
1-day move
-3.22%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a wider-than-expected loss per share but did not provide revenue figures. The stock fell 3.22% in response to the lack of guidance and management's cautious tone regarding market challenges. Investors may be concerned about the company's ability to navigate these issues moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | +3.01% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions affecting performance. They reiterated their commitment to long-term objectives without offering specific guidance.
Management highlighted ongoing challenges in the market.
They emphasized the importance of focusing on long-term goals despite short-term setbacks.
There was no specific guidance provided for future quarters.